-
公开(公告)号：EP3630121A1
公开(公告)日：2020-04-08
申请号：EP18810657.9
申请日：2018-05-30
申请人： Aurin Biotech Inc.
IPC分类号： A61K31/603 , A61K31/194 , A61K31/616 , C07C65/105 , C07C66/00 , C07C69/145 , G01N33/48
-
公开(公告)号：EP3491383A1
公开(公告)日：2019-06-05
申请号：EP17833139.3
申请日：2017-07-24
申请人： Aurin Biotech Inc.
IPC分类号： G01N33/53 , A61K45/00 , A61P25/28 , A61P29/00 , G01N33/577
-
公开(公告)号：EP3071543B1
公开(公告)日：2019-10-02
申请号：EP14862004.0
申请日：2014-11-17
申请人： Aurin Biotech Inc.
IPC分类号： C07C69/12 , A61K31/616 , A61P37/02 , A61K8/37 , A61Q5/00 , A61Q7/00 , A61Q19/00 , A61K9/00 , C07C69/017 , C07C69/16
-
公开(公告)号：EP2928460B1
公开(公告)日：2017-12-27
申请号：EP13860898.9
申请日：2013-06-21
申请人： Aurin Biotech Inc.
IPC分类号： A61K9/06 , A61K9/08 , A61K31/194 , A61K47/10 , A61K47/46 , A61P17/00 , A61P17/02 , A61P17/04 , A61P17/06 , A61P17/08 , A61P17/10 , A61P17/14
CPC分类号： A61K31/194 , A61K9/0014 , A61K9/06 , A61K47/10 , A61K47/46 , A61K2300/00
摘要： This invention describes a method of preventing and treating inflammatory skin diseases by topical application of aurin tricarboxylic acid and its derivatives. Such diseases are characterized by immune attack, especially involving aberrant complement activation. The diseases include, but are not limited to, androgenetic alopecia (baldness), seborrheic dermatitis/dandruff, allergic dermatitis, primary cicatricial alopecia, pemphigus, psoriasis, discoid lupus erythematosis, and dermatitus herpetiformis.
-
5.发明公开ACETYL SALICYCLIC ACID DIMERS, SYNTHESIS THEREOF, AND USES THEREOF TO PREVENT AND TREAT COMPLEMENT-MEDIATED DISORDERS 审中-公开ACETYLSALICYLSÄUREDIMERE，其合成和用途及其用于预防和疾病治疗补体介导
公开(公告)号：EP3071543A1
公开(公告)日：2016-09-28
申请号：EP14862004.0
申请日：2014-11-17
申请人： Aurin Biotech Inc.
IPC分类号： C07C69/12 , A61K31/616 , A61P37/02
CPC分类号： C07C69/16 , A61K8/375 , A61K9/0014 , A61Q5/006 , A61Q7/00 , A61Q19/004 , A61Q19/008 , C07C69/017 , Y02A50/411
摘要： Dimers of acetyl salicylic acid, including 4,4′-diacetoxy-[1,1′-biphenyl]-3,3′-dicarboxylic acid (DAS-1) and 5,5′-methylenebis(2-acetoxybenzoic acid) (DAS-2) are provided. Methods of blocking the C3 convertase stage of the alternative complement pathway, preventing formation of the membrane attack complex of complement, and preventing or treating a complement-mediated disorder in a mammal including the step of administering dimers of acetyl salicylic acid are also provided.
摘要翻译： 乙酰水杨酸的二聚体，包括4,4'-二乙酰氧基 - [1,1'-联苯] -3,3'-二羧酸（DAS-1）和5,5'-亚甲基双（2-乙酰氧基苯甲酸）（DAS -2）被提供。 因此提供阻断补体旁路途径的C3转化阶段，防止形成补体的膜攻击复合物，以及预防或治疗哺乳动物包括投乙酰水杨酸的二聚体的步骤的补体介导的病症的方法。
-
6.发明公开SELECTIVE INHIBITION OF THE MEMBRANE ATTACK COMPLEX OF COMPLEMENT AND C3 CONVERTASE BY LOW MOLECULAR WEIGHT COMPONENTS OF THE AURIN TRICARBOXYLIC ACID SYNTHETIC COMPLEX 审中-公开补体和C3转化BY低分子量组分合成金精三复杂的膜攻击复合物的选择性抑制
公开(公告)号：EP2872130A1
公开(公告)日：2015-05-20
申请号：EP12880850.8
申请日：2012-07-13
申请人： Aurin Biotech Inc.
发明人： MCGEER, Patrick , LEE, Moonhee , GUO, Jian-Ping , SCHWAB, Claudia
IPC分类号： A61K31/194 , A61P37/02 , C12N9/64
CPC分类号： C12Y304/21043 , A61K31/194 , C12N9/6424 , Y02A50/411
摘要： Selective inhibition of the membrane attack complex of complement in a mammalian species, preferably human, with components of the aurin tricarboxylic acid complex of less than 1 kilodalton in molecular weight. Preferred inhibitors are aurin tricarboxylic acid, aurin quadracarboxylic acid and aurin hexacarboxylic acid. Preferred disease to be treated by elective inhibition of the membrane attack complex of complement are age-related macular degeneration, Alzheimer's disease, atherosclerosis, rheumatoid arthritis, paroxysmal nocturnal hemoglobinemia, malaria infection and multiple sclerosis.
-
7.发明公开SELECTIVE INHIBITION OF THE MEMBRANE ATTACK COMPLEX OF COMPLEMENT AND C3 CONVERTASE BY LOW MOLECULAR WEIGHT COMPONENTS OF THE AURIN TRICARBOXYLIC ACID SYNTHETIC COMPLEX 审中-公开补体和C3转化BY低分子量组分合成金精三复杂的膜攻击复合物的选择性抑制
公开(公告)号：EP2872130A4
公开(公告)日：2016-06-22
申请号：EP12880850
申请日：2012-07-13
申请人： AURIN BIOTECH INC
发明人： MCGEER PATRICK , LEE MOONHEE , GUO JIAN-PING , SCHWAB CLAUDIA
IPC分类号： A61K31/194 , A61P37/02 , C12N9/64
CPC分类号： C12Y304/21043 , A61K31/194 , C12N9/6424
摘要： Selective inhibition of the membrane attack complex of complement in a mammalian species, preferably human, with components of the aurin tricarboxylic acid complex of less than 1 kilodalton in molecular weight. Preferred inhibitors are aurin tricarboxylic acid, aurin quadracarboxylic acid and aurin hexacarboxylic acid. Preferred disease to be treated by elective inhibition of the membrane attack complex of complement are age-related macular degeneration, Alzheimer's disease, atherosclerosis, rheumatoid arthritis, paroxysmal nocturnal hemoglobinemia, malaria infection and multiple sclerosis.
-
8.发明公开ACETYL SALICYCLIC ACID DIMERS, SYNTHESIS THEREOF, AND USES THEREOF TO PREVENT AND TREAT COMPLEMENT-MEDIATED DISORDERS 审中-公开ACETYLSALICYLSÄUREDIMERE，SYNTHESE DAVON UND VERWENDUNGEN DAVON ZUR VORBEUGUNG UND BEHANDLUNG VON KOMPLEMENTVERMITTELTEN KRANKHEITEN
公开(公告)号：EP3071543A4
公开(公告)日：2017-07-26
申请号：EP14862004
申请日：2014-11-17
申请人： AURIN BIOTECH INC
发明人： MCGEER PATRICK L , LEE MOONHEE , MCGEER EDITH G
IPC分类号： C07C69/12 , A61K8/37 , A61K9/00 , A61K31/616 , A61P37/02 , A61Q5/00 , A61Q7/00 , A61Q19/00 , C07C69/017 , C07C69/16
CPC分类号： C07C69/16 , A61K8/375 , A61K9/0014 , A61Q5/006 , A61Q7/00 , A61Q19/004 , A61Q19/008 , C07C69/017
摘要： Dimers of acetyl salicylic acid, including 4,4′-diacetoxy-[1,1′-biphenyl]-3,3′-dicarboxylic acid (DAS-1) and 5,5′-methylenebis(2-acetoxybenzoic acid) (DAS-2) are provided. Methods of blocking the C3 convertase stage of the alternative complement pathway, preventing formation of the membrane attack complex of complement, and preventing or treating a complement-mediated disorder in a mammal including the step of administering dimers of acetyl salicylic acid are also provided.
摘要翻译： 包括4,4'-二乙酰氧基 - [1,1'-联苯] -3,3'-二羧酸（DAS-1）和5,5'-亚甲基双（2-乙酰氧基苯甲酸）（DAS -2）。 还提供了阻断替代补体途径的C3转化酶阶段，阻止补体膜攻击复合物形成以及预防或治疗哺乳动物补体介导的病症的方法，包括施用乙酰水杨酸二聚体的步骤。
-
公开(公告)号：EP2928460A4
公开(公告)日：2016-08-17
申请号：EP13860898
申请日：2013-06-21
申请人： AURIN BIOTECH INC
发明人： MCGEER PATRICK L , LEE MOONHEE , BELL DOUGLAS N
IPC分类号： A61K31/194 , A61K9/06 , A61K9/08 , A61P17/00 , A61P17/04 , A61P17/06 , A61P17/08 , A61P17/10 , A61P17/14
CPC分类号： A61K31/194 , A61K9/0014 , A61K9/06 , A61K47/10 , A61K47/46 , A61K2300/00
摘要： This invention describes a method of preventing and treating inflammatory skin diseases by topical application of aurin tricarboxylic acid and its derivatives. Such diseases are characterized by immune attack, especially involving aberrant complement activation. The diseases include, but are not limited to, androgenetic alopecia (baldness), seborrheic dermatitis/dandruff, allergic dermatitis, primary cicatricial alopecia, pemphigus, psoriasis, discoid lupus erythematosis, and dermatitus herpetiformis.
-
公开(公告)号：EP2928460A1
公开(公告)日：2015-10-14
申请号：EP13860898.9
申请日：2013-06-21
申请人： Aurin Biotech Inc.
IPC分类号： A61K31/194 , A61P17/00
CPC分类号： A61K31/194 , A61K9/0014 , A61K9/06 , A61K47/10 , A61K47/46 , A61K2300/00
摘要： Methods of treating inflammatory skin conditions comprising topically administering a therapeutically effective amount of aurin tricarboxylic acid (ATA), aurin quadracarboxylic acid (AQA), aurin hexacarboxylic acid (AHA), or a combination thereof are provided. The inflammatory skin conditions may include acne vulgaris, allergic dermatitis, alopecia areata, androgenetic alopecia, atopic dermatitis, dandruff, dermatitis herpetiformis, discoid lupus erythematosus, pemphigus, primary cicatricial alopecia, psoriasis, seborrheic dermatitis, and ultraviolet and thermal burns.
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.009 秒)
